Get the Stockscreener App
22.22
5.57%
-1.31
Legend Biotech Corp Adr stock is traded at $22.22, with a volume of 1.69M.
It is down -5.57% in the last 24 hours and down -24.37% over the past month.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$23.53
Open:
$22.8
24h Volume:
1.69M
Relative Volume:
0.65
Market Cap:
$4.30B
Revenue:
$1.14B
Net Income/Loss:
$-250.98M
P/E Ratio:
-16.34
EPS:
-1.36
Net Cash Flow:
$-251.61M
1W Performance:
-0.18%
1M Performance:
-24.37%
6M Performance:
+16.89%
1Y Performance:
-49.74%
1-Day Range:
$22.18
$23.15
1-Week Range:
$22.05
$24.05
52-Week Range:
$16.24
$44.17
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Name
Legend Biotech Corp Adr
Sector
Industry
Phone
-
Address
-
Compare LEGN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
22.22 | 4.30B | 1.14B | -250.98M | -251.61M | -1.36 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jan-22-26 | Downgrade | TD Cowen | Buy → Hold |
| Jan-07-26 | Initiated | Oppenheimer | Outperform |
| Oct-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Jun-17-24 | Initiated | Truist | Buy |
| May-24-24 | Reiterated | H.C. Wainwright | Buy |
| May-23-24 | Initiated | Deutsche Bank | Buy |
| Apr-17-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | Raymond James | Outperform |
| Dec-19-23 | Initiated | Scotiabank | Sector Perform |
| Nov-06-23 | Initiated | Goldman | Buy |
| May-25-23 | Initiated | William Blair | Mkt Perform |
| May-22-23 | Initiated | Daiwa Securities | Buy |
| Mar-29-23 | Initiated | H.C. Wainwright | Buy |
| Mar-24-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-22 | Initiated | UBS | Buy |
| Nov-02-22 | Initiated | Evercore ISI | Outperform |
| Nov-01-22 | Initiated | Cowen | Outperform |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Mar-15-22 | Initiated | Barclays | Overweight |
| Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-21-21 | Initiated | Piper Sandler | Overweight |
| May-18-21 | Initiated | BTIG Research | Buy |
| Jul-01-20 | Initiated | JP Morgan | Overweight |
| Jul-01-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Morgan Stanley | Overweight |
View All
Legend Biotech Corp Adr Stock (LEGN) Latest News
UBS downgrades Legend Biotech stock rating on competition concerns - Investing.com
Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO) - The Globe and Mail
H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales - Investing.com
JPMorgan resumes Legend Biotech stock coverage with neutral rating By Investing.com - Investing.com South Africa
JPMorgan resumes Legend Biotech stock coverage with neutral rating - Investing.com
Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
LEGNLegend Biotech Corp ADR Options - Finviz
Legend Biotech (LEGN) CEO Ying Huang makes charitable gift of 3,382 shares - Stock Titan
Form 144 Legend Biotech Corp For: 30 June By Investing.com - Investing.com India
Form 4 Legend Biotech Corp For: 29 June By Investing.com - Investing.com India
Legend Biotech CEO Huang Ying sells $82,265 in shares By Investing.com - Investing.com South Africa
Legend Biotech CEO Huang Ying sells $82,265 in shares - Investing.com
Form 144 Legend Biotech Corp For: 26 June By Investing.com - Investing.com South Africa
Legend Biotech (LEGN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Legend Biotech Corp. Sponsored ADR Actuals & Estimates (NASDAQ:LEGN) - TradingView
9LB Forecast — Price Target — Prediction for 2027 - TradingView
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching - AOL.com
Form 6K Legend Biotech Corp For: 22 June By Investing.com - Investing.com South Africa
Form 424B5 Legend Biotech Corp - StreetInsider
Legend Biotech (LEGN) raises ~$211.6M selling 7.7M ADSs; option for 1.155M more - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Why Is Legend Biotech Stock Falling Thursday? - Benzinga
Legend Biotech prices $226 million public offering at $29.35 By Investing.com - Investing.com South Africa
Legend Biotech prices $226 million public offering at $29.35 - Investing.com
Legend Biotech launches $225 million public share offering - Investing.com
Legend Biotech stock falls on $225M share offering plan - Investing.com
Legend Biotech (NASDAQ: LEGN) files $225M ADS offering to fund pipeline - Stock Titan
Legend Biotech stock falls on $225M share offering plan By Investing.com - Investing.com India
Legend Biotech reports early trial success for in vivo CAR-T therapy - Investing.com
Legend Biotech reports early trial success for in vivo CAR-T therapy By Investing.com - Investing.com South Africa
UBS raises Legend Biotech stock price target on NHL therapy outlook By Investing.com - Investing.com South Africa
UBS raises Legend Biotech stock price target on NHL therapy outlook - Investing.com
GENSCRIPT BIO Spikes 19% as Legend Biotech Corporation (LEGN.US) Announces Positive Prelim Clinical Data for Lymphoma Therapy - aastocks.com
Cancer Drug Proves 100% Successful In Early Study; What's Next? - Investor's Business Daily
Keep an eye on the top gainers and losers in Tuesday's session. - ChartMill
Legend Biotech reports phase 1 data for in vivo CAR-T therapy - Investing.com
RBC Capital reiterates Legend Biotech stock rating at Outperform By Investing.com - Investing.com South Africa
RBC Capital reiterates Legend Biotech stock rating at Outperform - Investing.com
H.C. Wainwright reiterates Legend Biotech stock rating at buy - Investing.com
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use - Yahoo Finance
H.C. Wainwright reiterates Legend Biotech stock rating at buy By Investing.com - Investing.com South Africa
CANCTema Oncology ETF Stock Price and Quote - Finviz
GENSCRIPT BIO (01548.HK): Legend Biotech Corporation (LEGN.US) Presents Multiple Research Findings at ASCO Annual Meeting in the US - AASTOCKS.com
Earnings call transcript: Legend Biotech reports Q1 2026 loss, stock surges 12% - Investing.com
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals - AOL.com
Legend Biotech Corp Adr Stock (LEGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Legend Biotech Corp Adr Stock (LEGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Huang Ying | Chief Executive Officer |
Jun 25 '26 |
Sale |
14.78 |
5,566 |
82,265 |
241,872 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):